GLAXOSMITHKLINE PLC Form 6-K October 12, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending 12 October 2016

GlaxoSmithKline plc (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

GlaxoSmithKline plc (the 'Company') Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')			
a)	Name	Sir Andrew Witty		
b)	Position/status	Chief Executive Officer		
- )	Initial notification/			
c)	amendment	Initial notification		
~	Details of the issuer, emission allowance	market participant, auction		
2.	platform, auctioneer or auction monitor			
a)		GlaxoSmithKline plc		
	LEI	5493000HZTVUYLO1D793		
- /	Details of the transaction(s): section to b	e repeated for (i) each type of		
3	instrument; (ii) each type of transaction;			
	where transaction(s) has been conducted			
	where transaction(s) has been conducted	Ordinary shares of 25 pence each		
		('Ordinary Shares')		
a)	Description of the financial instrument	ISIN: GB0009252882		
		ISIN. OB0009232882		
		A aquisition of Ordinary Shares		
		Acquisition of Ordinary Shares		
b)	Nature of the transaction	under the Company's ShareReward Plan.		
		ShareReward Plan.		
``	Price(s) and	Price(s) Volume(s)		
c)	volume(s)	£17.2781 7 (partnership shares)		
		£17.2781 7 (matching shares)		
	Aggregated information			
d)		14 Ordinary Shares		
	Aggregated volume Price	£17.2781		
ABBIOSARCA VOTATION I TICO				
e)	Date of the transaction	2016-10-11		
f)	Place of the transaction	London Stock Exchange (XLON)		
	Details of PDMR/person closely associated			
a)	Name	Mr R G Connor		
b)	Position/status	President, Global Manufacturing		
0)		& Supply		
c)	Initial notification/	Initial notification		
0)	amendment	Initial notification		
2. Details of the issuer, emission allowance market participant, auction				
∠.	platform, auctioneer or auction monitor			
a)	Name	GlaxoSmithKline plc		
b)	LEI	5493000HZTVUYLO1D793		
	Details of the transaction(s): section to be repeated for (i) each type of			
~	instrument; (ii) each type of transaction; (iii) each date; and (iv) each place			

	Logar i mig	
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's ShareReward Plan.
c)	Price(s) and volume(s)	Price(s)Volume(s)£17.27817 (partnership shares)£17.27817 (matching shares)
d)	Aggregated information Aggregated volume Price	14 Ordinary Shares £17.2781
e) f)	Date of the transaction Place of the transaction	2016-10-11 London Stock Exchange (XLON)
<ul> <li>a)</li> <li>b)</li> <li>c)</li> <li>2.</li> <li>a)</li> <li>b)</li> </ul>	Details of PDMR/person closely associa Name Position/status Initial notification/ amendment Details of the issuer, emission allowance platform, auctioneer or auction monitor Name LEI Details of the transaction(s): section to b instrument; (ii) each type of transaction; where transaction(s) has been conducted	Mr S Dingemans Chief Financial Officer Initial notification e market participant, auction GlaxoSmithKline plc 5493000HZTVUYLO1D793 e repeated for (i) each type of (iii) each date; and (iv) each place Ordinary shares of 25 pence each
a)	Description of the financial instrument	('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's ShareReward Plan.
c)	Price(s) and volume(s)	Price(s)Volume(s)£17.27817 (partnership shares)£17.27817 (matching shares)
d)	Aggregated information	14 Ordinary Shares

Aggregated volume Price

- e) Date of the transaction 2016-10-11
- Place of the transaction f) London Stock Exchange (XLON)
- 1. Details of PDMR/person closely associated with them ('PCA') a) Name Mr N Hirons b) Position/status SVP, Global Ethics & Compliance Initial notification/ c) Initial notification amendment Details of the issuer, emission allowance market participant, auction 2. platform, auctioneer or auction monitor a) Name GlaxoSmithKline plc b) LEI 5493000HZTVUYLO1D793 Details of the transaction(s): section to be repeated for (i) each type of 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted Ordinary shares of 25 pence each ('Ordinary Shares') a) Description of the financial instrument ISIN: GB0009252882 Acquisition of Ordinary Shares under the Company's b) Nature of the transaction ShareReward Plan. Price(s) Volume(s) Price(s) and £17.2781 8 (partnership shares) c) volume(s) £17.2781 8 (matching shares) Aggregated information 16 Ordinary Shares d) £17.2781 Aggregated volume Price e) Date of the transaction 2016-10-11 Place of the transaction f) London Stock Exchange (XLON)
- 1. Details of PDMR/person closely associated with them ('PCA') Mr S A Hussain a) Name b) Position/status President, Global Pharmaceuticals Initial notification/ Initial notification c) amendment Details of the issuer, emission allowance market participant, auction 2. platform, auctioneer or auction monitor a) Name GlaxoSmithKline plc 5493000HZTVUYLO1D793
- b) LEI

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882

- a) Description of the financial instrument
- Acquisition of Ordinary Shares under the Company's b) Nature of the transaction ShareReward Plan. Price(s) Volume(s) Price(s) and £17.2781 7 (partnership shares) C) volume(s) £17.2781 7 (matching shares) Aggregated information 14 Ordinary Shares d) £17.2781 Aggregated volume Price P to of the two was at 2016 10 11

e)	Date of the transaction	2016-10-11
f)	Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA') a) Name Mr D S Redfern b) Position/status Chief Strategy Officer Initial notification/ Initial notification c) amendment Details of the issuer, emission allowance market participant, auction 2. platform, auctioneer or auction monitor a) Name GlaxoSmithKline plc 5493000HZTVUYLO1D793 b) LEI Details of the transaction(s): section to be repeated for (i) each type of 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted Ordinary shares of 25 pence each ('Ordinary Shares') a) Description of the financial instrument ISIN: GB0009252882 Acquisition of Ordinary Shares under the Company's b) Nature of the transaction ShareReward Plan. Volume(s) Price(s) Price(s) and £17.2781 8 (partnership shares) c) volume(s)

£17.2781 8 (matching shares)

	Aggregated information	
d)	Aggregated volume Price	16 Ordinary Shares £17.2781
e)	Date of the transaction	2016-10-11
f)	Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

1.	Details of I Diving person closely associa	
a)	Name	Ms C Thomas
b)	Position/status	SVP, Human Resources
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance platform, auctioneer or auction monitor	e market participant, auction
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
-	Details of the transaction(s): section to b	e repeated for (i) each type of
3.	instrument; (ii) each type of transaction;	(iii) each date; and (iv) each place
	where transaction(s) has been conducted	
		Ordinary shares of 25 pence each
a)	Description of the financial instrument	('Ordinary Shares')
<i>a)</i>	Description of the finaletar instrument	ISIN: GB0009252882
		Acquisition of Ordinary Shares
b)	Nature of the transaction	under the Company's
0)		ShareReward Plan.
		<b>-</b> · · · · · · · · · · · · · · · · · · ·
``	Price(s) and	Price(s) Volume(s)
c)	volume(s)	£17.2781 8 (partnership shares)
		£17.2781 8 (matching shares)
	Aggregated information	16 Ordinary Shares
d)	Aggregated mormation	£17.2781
u)	Aggregated volume Price	217.2781
	Aggregated volume Thee	
e)	Date of the transaction	2016-10-11
	Place of the transaction	
f)		London Stock Exchange (XLON)

1.	Details of PDMR/person close	sely associated with them ('PCA')
a)	Name	Mr P C Thomson

b) Position/status Government Affairs	a) Name	Mr P C Thomson
Government Affairs	b) Position/status	SVP, Communications &
c) Initial notification/ Initial notification	b) Toshion/status	Government Affairs
	c) Initial notification/	Initial notification

amendment

- 2. Details of the issuer, emission allowance market participant, auction
- <sup>2</sup>. platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
- Details of the transaction(s): section to be repeated for (i) each type of
- 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

- a) Description of the financial instrument ISIN: GB0009252882
- b) Nature of the transaction
   c) Price(s) and volume(s)
   d)
   Aggregated information
   Aggregated information

Aggregated volume Price

e)	Date of the transaction	2016-10-11
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')			
a)	Name	Dr P J T Vallance		
b)	Position/status	President, Pharmaceuticals R&D		
c)	Initial notification/ amendment	Initial notification		
r	Details of the issuer, emission allowance	e market participant, auction		
2.	platform, auctioneer or auction monitor			
a)	Name	GlaxoSmithKline plc		
b)	LEI	5493000HZTVUYLO1D793		
	Details of the transaction(s): section to b	e repeated for (i) each type of		
3.	instrument; (ii) each type of transaction; (iii) each date; and (iv) each place			
	where transaction(s) has been conducted			
0)		Ordinary shares of 25 pence each ('Ordinary Shares')		
a)	Description of the financial instrument	ISIN: GB0009252882		
		Acquisition of Ordinary Shares		
h)	Nature of the transaction	under the Company's		
b)		ShareReward Plan.		

c)	Price(s) and volume(s)	£17.2781	Volume(s) 7 (partnership shares) 7 (matching shares)
d)	Aggregated information Aggregated volume Price	14 Ordinai £17.2781	ry Shares
e) f)	Date of the transaction Place of the transaction	2016-10-1 London St	1 ock Exchange (XLON)
a)	Details of PDMR/person closely associa Name Position/status	ted with the Ms E Walt CEO Desig	msley
c)	Initial notification/ amendment	Initial noti	fication
b)	Details of the issuer, emission allowance platform, auctioneer or auction monitor Name LEI Details of the transaction(s): section to b instrument; (ii) each type of transaction; where transaction(s) has been conducted	GlaxoSmit 5493000H e repeated f (iii) each d	thKline plc ZTVUYLO1D793 for (i) each type of
a)	Description of the financial instrument	('Ordinary	shares of 25 pence each Shares') 0009252882
b)	Nature of the transaction		n of Ordinary Shares Company's ard Plan.
c)	Price(s) and volume(s)	Price(s) £17.2781 £17.2781	Volume(s) 8 (partnership shares) 8 (matching shares)
d)	Aggregated information Aggregated volume Price	16 Ordinaı £17.2781	ry Shares
e) f)	Date of the transaction Place of the transaction	2016-10-1 London St	1 ock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mrs V A Whyte

b)	Position/status	Company	Secretary
c)	Initial notification/ amendment	Initial not	ification
2.	Details of the issuer, emission allowance platform, auctioneer or auction monitor	rticipant, auction	
a)	Name	GlaxoSmi	thKline plc
b)	LEI	5493000H	IZTVUYLO1D793
	Details of the transaction(s): section to b	e repeated	for (i) each type of
3.	instrument; (ii) each type of transaction;	(iii) each d	late; and (iv) each place
	where transaction(s) has been conducted		
a)	Description of the financial instrument	('Ordinary	shares of 25 pence each / Shares') 0009252882
b)	Nature of the transaction	-	on of Ordinary Shares Company's yard Plan.
c)	Price(s) and volume(s)	£17.2781	Volume(s) 7 (partnership shares) 7 (matching shares)
d)	Aggregated information Aggregated volume Price	14 Ordina £17.2781	ry Shares
e)	Date of the transaction	2016-10-1	1
E.	Place of the transaction		
f)		London S	tock Exchange (XLON)

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc (Registrant) Date: October 12, 2016

#### By: VICTORIA WHYTE

-----

Authorised Signatory for and on behalf of GlaxoSmithKline plc